

A Current Prospective on Nano-Carriers for Mitigation of Neuro-Dysfunction Disorders

Harpreet Kaur Sangha¹, Manoj Kumar Katual^{2*}, Chander Mohan³, Gurfateh Singh⁴

¹²³Department of pharmaceuticals, RayatBahra Institute of Pharmacy, Hoshiarpur, Punjab, India

⁴University school of Pharmaceutical Sciences, RayatBahra University, Mohali, Punjab, India

ABSTRACT–Nano-particles are boon of nano-biotechnology which emerges out in last 2- 3 decades which has proven itself a break-through for treatment of central nervous system disorders like Alzheimer's disease, Parkinson's disease, Epilepsy, Hodgkin's disease, Schizophrenia, Glioblastoma and many more. The brain is naturally protected by blood brain barrier and non-permeable to majority of nutrients as well as drug components, which cause hinders to proper treatment as the drug is incapable to cross BBB to reach target site of CNS. Consequently, the need of novel and effective delivery systems are developed which are capable of carrying drugs to target site with high bioavailability. The positive aspects which the Nanoparticles carry is high permeability due to internal compartmentalization to targeted sites the on an average size which are for Nano delivery is about 500 to 600 nanometres but the site specific drug delivery the techniques involves in manufacturing classification and characterization parameters are enlighten in this review article. The Nano- biotechnology has a plethora of possibilities in furthest study.

Keywords: carbon nanotubes, dendrimers, nanocarriers, Nano-carries, Neuro-dysfunction, polymerized nanocarriers.

*Corresponding Author

Dr. Manoj Kumar Katual

University school of Pharmaceutical Sciences, RayatBahra University, Mohali, Punjab, India

manojkumar.katual@gmail.com

First author's Email- hss2sangha@gmail.com

1. INTRODUCTION

Nanoparticles are derived from Greek word “nanos” and Latin word “particulum” which mean dwarf particles. Nanoparticles are fine agents in Nano size from range 1 to 1000 nm in diameter. Nanoparticle can be single particles or aggregates. Nanoparticles can be composed of chemical composition like metals, semiconductor material, compound such as metal oxide (inorganic nanoparticles) or of carbon containing molecules such as polymers (organic compounds). Carbon based nanoparticles are spherical in shape or cylindrical nanotubes for e.g. carbon black

Nanoparticles are classified based upon different size and shape of nanoparticles. Depending upon shape which based upon structure and form, nanoparticles are found to be in spheres, needles or tubes, pellets and fibers while, based upon size it is divided into ultrafine nanoparticles (1 to 100nm), fine nanoparticles (100 to 2500 nm) and coarse particles (2500 to 10000 nm). Nanocarriers are nanoparticles used as carriers to deliver drug at target site, in which drug is encapsulated in nanoparticle or, absorbed or covalently attached to the nanoparticle surface. Target site is achieved by drug via, active or passive methods. Active method involves variation in physical conditions like pH, temperature, magnetism to get nanoparticle to target site while passive

method consists variation in vascular permeability and retention parameters.

2. TYPES OF NANOPARTICLES

There are different types of nano carriers like polymers emulsions, Lipo-carriers, solid lipid carriers, carbon nanotubes, metal based carriers etc.

2.1 Liposome : Liposomes are lipid bilayered spherical vessels of size 80 to 300 nm, attached with phospholipids, which are amphipathic in nature and characterized by hydrophilic head and lipophilic tail on the same core and steroids. In liposome, the aqueous core is surrounded by lipid layer and the inner aqueous form bulk outside as shown in fig.1. Liposome is manufactured by disturbance of membranes.




Figure 1: Structure of liposomes [1]

2.2 Polymers nanoparticles: PNP is solid, nanosized (10-1000nm) colloidal particles made up of biodegradable polymer, it can be nanosphere or nanocapsule. The drug in

encapsulate in the polymer matrix in nanosphere and liquid core of oil and water encapsulated by solid polymeric membrane in nanocapsules as shown in fig. 2.





Figure 2: Polymer Nanoparticles [2]

2.3 Dendrimersnanocarriers: dendrimers are branched macromolecules with originating arms from the core, Dendron and surface active group are attached to core covalently and its properties are determined by type of surface active group by nano-carrier as shown in figure 3. These are obtained by synthetic techniques and of average size 1.5 to 14.5 nm.



Dendrimers

Figure 3: Dendrimers [3]

2.4 Carbon nanoparticles: It consists of nanotubes and nanohorns. These are formed by single nanotube rolled in to sheet or multiply nanotubes managed concentrically as

shown in fig. 4.. The drug is encapsulated, absorbed or attached to active agents to the nanotubes. The drug can be released by physical or chemical modification.




Figure 4: Carbon Nanotubes [4]

2.5 Silica material nanoparticles: These are solid nanoparticles composed of mesoporous silica like MCM-41 silica or SAB -15 in Xerogel. It is of range of size 10 to 50nm. The drug is loaded on nanocarrier by adsorption and drug is released by diffusion mechanism in body.[16]

2.6 Metal based carriers: It consist of metal ions like silica, silver, gold etc. similar to silica based nanocarriers; other metal based carriers are formed.

3. PREPARATION TECHNIQUES

The preparation of nanoparticles is based upon physiochemical characters of polymer and the drug to be loaded for selection of method to use theperformed polymer of nanoparticles include following primary manufacturing methods:

3.1 Emulsion-solvent evaporation: It involves emulsification of polymer solution into aqueous phase the evaporation of

polymer solvent, which induce polymer precipitation as nanosphere. The nanospheres are collide by ultracentrifugation and washed with distilled waste to remove stabilizer residue or any free drug and lyophilized for storage. This technique is modified as higher pressure emulsification and solvent evaporation. This method involves homogenization of emulsion under pressure, followed by overall stirring to remove organic solvent used for liposoluble drug. The polymers used are PLA, PLGA, EC etc.[5]

3.2 Double emulsion and evaporation method:

Double emulsion technique is used to encapsulate hydrophilic drug which involves the addition of aqueous drug solution to organic polymer solution to form *W/O* emulsion in under vigorous stirring. The removal of solvent from emulsion by evaporation and nanoparticles are isolated by centrifugation at high speed. Before lyophilization wash the formed nanoparticles.[6]

3.3 Salting out method: This method is based upon division of water miscible solvent from aqueous solution via a salting out effect. Firstly, drug and polymer are dissolved in a solvent which is emulsified later into an aqueous gel containing salting out agents (electrolytes) and colloidal stabilizer. The diffusion of solvent to aqueous phase by dilution is enhanced by dilution of oil/water emulsion in adequate volume of water or aqueous solution, this induce nanosphere formation. [7]

3.4 Emulsion-diffusion method:

Encapsulated polymer is dissolved in partially water-miscible solvents (propylene carbonate,

benzyl chloride) and to ensure the initial thermodynamics equilibrium of both the liquids, is saturated with water. Later, the aqueous solution containing stabilizers are emulsified by polymer-water saturated solvent phase. According to oil to polymer ratio lead to solvent diffusion to external phase at the end acc. to boiling point by evaporation or filtration, the solvent is evaporated. The technique presents several advantages like high encapsulated efficiencies, no need to homogenization, high batch to batch predictability.[8]

3.5 Solvent displacement method:

Precipitation method: solvent displacement involves the diffusion of organic solvent in aqueous medium and precipitation of performed polymer from an organic solvent in the pressure or absence of surfactant. The solution of polymer, drug and or lipophilic surfactant dissolved in semi-polar water miscible solvent is poured or injected into an aqueous solution containing stabilizer under magnetic stirring. rapid solvent diffusion lead to formulation of nanoparticles. The solvent from suspension is removed by reduced pressure. [9]

4. NEURO-DYSFUNCTION

A disorder of central nervous system and affect the efficiency of brain process which can cause impediment in performing daily tasks are known as Neurological dysfunction.

4.1 Alzheimer's disease: It is progressive disease, can occur at any age group. It is characterized by disorientation, memory loss and aphasia indicate server cortical dysfunction, can cause dementia in the elderly

One out of each four is affected by this disorder which is double the number of patients in last half decade.[10]

4.2 Parkinson's disease: It is a progressive disorder of the nervous system that affects movement of the body like walking and talking. It leads to stiffness and slowing of movement. The common symptoms are shaking of hands, rigid muscles, slowed movements, impaired posture and balance, loss of memory and writing and speaking inability, observed in elders. It is caused by nerve cell damage in the brain which causes loss of dopamine. [11]

4.3 Schizophrenia: It is a serious mental disorder which affects clearly the ability to think, feel and behave, leading to difficulty in concentration and memory. Hallucination, delusion, disorganized speech and different behavior. Negative symptoms like emotional, lack of speech. The exact cause of schizophrenia is not known.[12]

4.4 Epilepsy: These are a class of unpredictable CNS disorders with variable frequency, which consist of symptoms of paroxysmal cerebral dysrhythmia, seizures (episodes) of disturbance or loss of alertness (consciousness), sensory or psychiatric phenomena with or without body movements (convulsions). Seizures observed are generalized seizures and partial seizures depending upon the origin of focus and region affected by the discharge of neurotransmitters in the brain. [13]

4.5 Glioblastoma: It is a rapidly growing brain tumor found in 1 out of 1000 patients of cancer, with limited ability of the brain to repair itself. The cause of this is not exactly known. It

is characterized by headache, seizures, difficulty in sleeping, swelling, change in personality or mood, nausea and inability to think etc.[14]

4.6 Hodgkin's disease: It is also known as Hodgkin's lymphoma. It is a cancer of the lymphatic system, which helps the immune system to get rid of waste and fight infections. It is caused when lymphocytes develop a genetic mutation, replication of ailing cells caused by it. [15]

5. OBJECTIVE OF STUDY

The current review article focuses on the current advancement of Nano-technological formulation for the problem associated with BBB restriction, less permeability update, lipophilicity constraint and size specificity constraint. The authors aimed towards enlightening the previews, present and further prospective towards nano-technological particulate drug delivery system for the betterment of mankind.

6. REVIEW OF LITERATURE

Resham Chhabra et al. (2015) suggested that the drug delivery from systemic circulation to the desired site of action i.e. CNS, is hindered by CNS barriers. Nanoscaled drug delivery systems are used to bypass the barriers. As these nanomedicine drugs are more effective than conventional drug delivery methods such as high drug loading capacity, targeted action, reduced toxicity, and increased therapeutic effect. Nano-neuroscience is thereby an emerging field for CNS therapeutics.[17]

You Young Kanget.al (2018)reported that neurological disorders have driven to annihilating results on the human open wellbeing. Of these clutters, early diagnostics remains destitute, and no treatment has been effectively found; they ended up the foremost life-threatening restorative burdens the world compared to other major infections. The blood brain barrier is major challenge for treatment of neurological disorders as BBB cause obstacle to reach drug at target site. The limiting drug entry into brain and unwanted neuro immune activities lead to irreversible neuronal damage by untargeted drugs. The recent advancement of nanotechnology contributes to development of novel nanoplateform and effective delivery of drug to improve treatment of CNS disorder. Nanomedicines are functionalized with targeting ligands to improve efficiency, bioavailability and permeability of drug to reach target site [24]. [1] suggested that nanocarries incorporate the improvement nanoparticles competent of detached and dynamic focusing on as well as those are responsive to different inside and external triggers. Nanocarriers can moreover give numerous of the preference of lipid framework. Liposome, strong lipid Nanoparticle, Nanoemulsion, Dendrimers, polymeric nanoparticle is the case of sedate conveyance framework.

[10] explained that the CNS, one of the foremost fragile a micro environments of the body is secured by the BBB regulating its homeostasis. BBB may be the a exceedingly complex structure that firmly controls the development of the particles of a constrained

number of little atoms and of an indeed more limited number of macromolecules from the blood to the brain, ensuring it from wounds and illnesses. In ant case, the BBB moreover essentially blocks the conveyance of drugs to the brain, in this way, anticipating the treatment of a number of neurological disorders.

Jayanta Kumar Patra et al. (2018) stated that nano medicine and nano delivery systems are new and rapidly growing science which utilized to serve as diagnostic tools or to deliver drugs at nanoscale range to targeted site in controlled manner. Nanotechnology offers various benefits in treating chronic diseases by site-specific and target-oriented delivery of precise medicines. [7]

[6] suggested that the blood- brain barrier gives security for the brain but too prevents the treatment and determination of neurological disorders, the drugs must cross the BBB to reach the damaged part of brain. Hence, consideration has turned to creating novel and viable conveyance system that are competent of carrying sedate which provide great bioavailability within brain. Nanoneurotechnology, particularly application of nanoparticles is steady movement, has given promising answers to a number to a number of these issues in afterward time.

[11] reported that nanotechnological applications offer an elective stage for the treatment of neurodegenerative disorders like Alzheimer's disease. A abundance of nanocarriers and nanoparticle prodrug have been detailed to have insignificant cytotoxicity in creature models, and these

advancements have uncovered modern classes of strong medicate details for AD. Distinctive nanotechnology-based approaches such as polymers, emulsions, Lipo-carriers, strong lipid carriers, carbon nanotubes and metal-based carriers have been created over the past decade, and they have been centering on both neuroprotective and neurogenerative strategies to treat AD. Considers moreover uncover that nanotechnological approaches can help in early conclusion of AD improve helpful viability and bioavailability.

[18] explained that Central nervous system (CNS) clutters particularly neurodegenerative disarranges are the major challenge for open wellbeing and request the extraordinary consideration of analysts to secure individuals against them. In past few decades, distinctive treatment methodologies have been embraced, but their helpful viability are not sufficient and have as it were appeared halfway relief of indications. Blood-brain boundary (BBB) and blood-cerebrospinal fluid barrier (BSCFB) watch the CNS from hurtful substances and posture as the major challenges in conveying drugs into CNS for treatment of CNS complications such as Alzheimer's illness (AD), Parkinson's disease (PD), Huntington's disease (HD), stroke, epilepsy, brain tumors, multi plesclerosis (MS), and encephalitis, etc. Nanotechnology has come out as an energizing and promising unused stage of treating neurological disarranges and has appeared incredible potential to overcome issues related to the customary treatment approaches. Particles can be nano engineered to carry out different Neuro protective agents like curcumin, edaravone.

[19] researched that nanotechnology based drug delivery systems are quite helpful to overcome the barriers in CNS treatment as powerful tool. Nanomedicine can easily cross and permeable through the biological barrier due to its small size and biofunctionized characteristics of nanoparticles. Nanomedicine is effective in CNS disorder treatment. SLN and PNP encapsulated drugs was reported highly viable and easily penetrating through BBB and some metallic nanocarriers were reported cytotoxic to brain.

[1] suggested that it is important to understand the physiochemical properties of drug as only 5% of tested/tried drugs are able to penetrate through BBB, it cause longer duration to sedate for CNS disorders. Only few drug delivery systems have potential to cross BBB and having less side effects.

[2] explained that the BBB and its effect on medication based treatment and nanoparticles are appropriate and adaptable contender for the improvement of novel and execution upgraded nanopharmaceuticals for neurogenerative conditions treatment. AD and PD are conditions discovered around the world, being viewed as the most widespread degenerative pathologies identified with CNS. The flow treatment of these include both clinical and trial draws near, principally empowers indication the board and auxiliary neuronal security and even less illness relapse. Since, nano techonolgy based material and gadgets demonstrated alluring and productive stages for current nanomedicine.[20] stated that the molecules uncover curiously properties at the measurement of underneath 100 nm, for the most part from two physical

impacts. The two physical impacts are the quantization of electronic states clearly driving to exceptionally touchy size-dependent impacts such as optical and attractive properties and the tall surface-to-volume proportion alters the warm, mechanical, and chemical properties of material. The nanoparticles' distinctive physical and chemical properties render them most fitting for a number of master application.

[10] explained that nanotechnology based drugs are designed based upon the unique properties and structure of nanocarriers, act a drug delivery vehicle to cross BBB to treat many neurological disorders.

[21] reported that nanotechnology is very effective in treatment of neurodegenerative diseases, and nano carriers play an important in it as target delivery system to treat various CNS related tumours. Nano carriers are designed accordingly that it can cross BBB and enhance the effectiveness of drug with nanomaterial.

[22] reviewed that complexity of few nanomedicine on a combination of targeting systems and agents for diagnostic effects that are response from stimuli or by external stimuli etc. and little degree of complexity is also required to interact with biological systems and fight against certain diseases and increased complexity is risk to threaten therapeutic result.

[23] stated that nanoparticle technology give manifesto for designing tissue specific drug delivery having movable and changeable nature. The Nanoparticles are designed to

cross BBB while maintaining the bioavailability of drug in CNS. The novel delivery with less interfering to treatment and diagnosis of neurological disorders are strategies of nano delivery.

7. DISCUSSION AND CONCLUSION

Nanoparticles display a profoundly alluring stage for diverse cluster for biological application especially in the CNS. Nanoparticle delivery system incredible potential being able to change over ineffectively solvent, ineffectively absorb and liable biological active substance into a promising deliverable drug. Nanoparticles due to small size or range cross the biological barriers of CNS i.e. brain blood barrier (BBB) and cerebrospinal fluid (CSF). Nanoparticle having hydrophilic shell which prevents deterioration of drug by endothelial system which prolong the duration of circulation of drug in the CNS. Nanomedicine play important role in medication as CNS-targeted drug in case of neurodysfunction diseases like PD, AD, schizophrenia and glioblastoma.

ACKNOWLEDGEMENT

The authors are hereby acknowledged the highly patronage of all faculty and staff members of RayatBahra Institute of Pharmacy, Hoshiarpur and RayatBahra University, Mohali for their much needed support and help. The authors hereby declare no interest in conflict. All the authors involved preparing of this review article, has equally contributed and supported.

REFERENCE

- [1] Ojah, A.Aarsland, D., Larsen, J.P., Tandberg, E., Laake, K (2018). Different types of nanocarriers for targeted treatments of HIV/AIDS, *Int J Curr Pharm.*, 11(4), 66-69.
- [2] Teleanu, D.M. Aggrawal G, dhawan S (2019). Nanomaterials for drug delivery to central nervous system, nanomaterials (basel). DOI 10.3390/nano903037
- [3] Surat, P. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J. (2020), Nanocarriers for drug delivery , *news-medical*, article no. 1
- [4] Din, F.Afroz, F., Bach, C., (2018), Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, *Int J*
- [5] Pasut, G. Alexis, F., Pridgen, E.M., Langer, R., Farokhzad, O.C.,(2019). Grand challenges in nano-based drug delivery. *Frontiers in medical Technology* , 1(1).
- [6] Kanwaret, J.R. Ballard, C.G., Aarsland, D., McKeith, I., (2018). Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. 8(4),399-414.
- [7] Patra, J. K. Begley, D., Brightman, M.W., (2018). Nano based drug delivery systems: recent developments and future prospects. *Journal of nanobiotechnology*, 16(71).
- [8] Alhawati, J. Berardelli, A, Rothwell, J.C., Thompson, P.D.,(2020). nanocarriers as Potential Drug Delivery Candidates for Overcoming the Blood–Brain Barrier: Challenges and Possibilities. *American chemical society*, 5(22),12583-12595.
- [9] Ranjit, K. Berardelli, A, Rothwell, J.C., Thompson, P.D., (2013). nanoparticle: An overview of preparation, characterization and application. *International research journal of pharmacy* , 4(4).
- [10] Siddiqi, K. S., Husen, A., Sohrab, S. S., & Yassin, M. O. (2018). Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management. *Nanoscale research letters*, 13(1), 231. <https://doi.org/10.1186/s11671-018-2638-7>
- [11] Tripathi. Bhatt, D., Ajmeri, N., Mandal, S., K.S., Rajesh, (2018). Textbook of essentials of medicinal pharmacology, 8th edition, Jaypee Brothers publishers. pp- 438
- [12] Kumar., Biousse, V., Skibell, B.C., Watts, R.L., (2008). Text book of pathologic Basic of Disease. pp. 1386 -1388. printed by press ltd. of India.
- [13] Saeedi, M. Blackett, H., Walker, R., Wood, B., (2019). applications of nanotechnology in drug delivery to the central nervous system. *biomedicine & pharmacotherapy*, 111, 666-675.
- [14] Masserini, M. Boeve, B.F., Silber, M.H., Saper, C.B., (2013). nanoparticles for brain delivery. *international scholarly research notices biochemistry*, article Id 238428 , 18 pages.
- [15] Zukunft, N.M.D. Borek, L.L., Kohn, R., Friedman, J.H., (2001). chemie in unsererzeit, 1,32-41.
- [16] Parkinson's disease newsletter.(2020). *mayo foundation for medical Education and research*.
- [17] Chhabra, R. Chandrakant singh V. Pardeshi., Veena S. Belgamwar., Avinash R. Tekade., Sanjay J. Surana., (2019). emerging use of nanotechnology in the treatment of neurological disorders. *curr pharm des.* 21(22),3111-30.
- [18] Navqiet. S. Devang Bhatt., Nisha Ajmeri., Surjyanarayan Mandal., Rajesh K. S., (2020).

- nanotechnology: A promising Approach for delivery of neuroprotective drugs. *frontiers in Neuroscience*, 14(494).
- [19] Soni, S. Elisabetta Esposito., Martina Fantin., Matteo Marti., Markus Drechsler., (2018), nanomedicine in central nervous system disorders. *A present and future prospective*. doi :10.3390/apd.2016.044
- [20] Pal, S.L. Forno, LS., Sternberger, LA., Sternberger, NH., (2011). *journal of Applied pharmaceutical Sciences* 01 (06), 228-234.
- [21] Celi, T.Fornstedt, B., Pileblad, E., Carlsson, A., (2020). Preparation of Nanoparticles. *creative commons attribution 3.0 licence*. DOI-10.5772/intechopen.90771
- [22] P.Gavrieli, Y., Sherman, Y., Ben-Sasson, SA., (2020). nano carrier drug delivery systems for the treatment of neuropsychiatric disorders: advantages and limitations. *molecules*, 25,5294
- [23] Sim, T.M. Fritsch T, K Smyth, M Wallendal, T Hyde, G Leo, (2020). Nanoparticle-Based Technology approaches to the management of neurological Disorders. *international journal of Neurological disorders*, 21, 6070.
- [24] Kang, Y.J. George, JM., Jin, H., Woods, WS., (2018). therapeutic nanoplatforms and delivery strategies for neurological disorders. *Nano convergence* 5(35).